A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel Group Study to Evaluate Safety, Tolerability and Pharmacodynamics of PF-06835919 Administered Daily for 16 Weeks in Adults With Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus on Metformin.